Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
Key Highlights
- ➤European Commission grants Adcomfo marketing authorization for biosimilar XOLAIR
- ➤Adcomfo previously received UK MHRA authorization in March 2026
- ➤U.S. application for proposed XOLAIR biosimilar remains under FDA review
- ➤600-patient CSU study met primary endpoint with equivalent efficacy and comparable safety
Expert Statements
Andy Boyer, Executive Vice President and Chief Commercial Officer – Affordable Medicines, Amneal
“Adcomfo approval by the European Commission is a proud achievement, reflecting years of scientific expertise, dedication and collaboration.”
Andy Boyer, Executive Vice President and Chief Commercial Officer – Affordable Medicines, Amneal
“This approval further demonstrates the strength of the capabilities supporting our expanding biosimilars portfolio.”
Andy Boyer, Executive Vice President and Chief Commercial Officer – Affordable Medicines, Amneal
“We see significant opportunity to broaden access to high-quality, affordable biologic medicines while building biosimilars into a durable, long-term growth driver for Amneal.”
* European Commission approval follows UK MHRA authorization of Adcomfo in March 2026 * U.S. application for proposed biosimilar of XOLAIR(® )currently under review BRIDGEWATER, N.J., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the European Commission (EC) has granted marketing authorization for Adcomfo(® )(omalizumab), a biosimilar to XOLAIR(®).
Adcomfo, also known as ADL-018/AVT23, was developed by Kashiv BioSciences LLC in collaboration with Alvotech. Amneal acquired Kashiv in August 2026. The European Commission approval follows the positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2026. Separately, Adcomfo received authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in March 2026. Together, these approvals represent important regulatory milestones for the program and expand Adcomfo’s reach across European markets.
Get started
Create a free account to read the full story.
